Sibutramine hydrochloride (SIBU) is a selective inhibitor of norepinephrine and serotonin reuptake with anorectic and thermogenic action. The most frequent side effects are dysgeusia and xerostomia. Our studies have shown that SIBU increases the relative and absolute weight and mucin levels of the submandibular glands (SM). The antioxidant defense imbalance may be associated with salivary gland dysfunctions. The objective of this work is to evaluate the non-enzymatic antioxidant defense by total iron reduction antioxidant power (FRAP), reduced glutathione (GSH) and uric acid (AU), besides the enzymatic defense that will be evaluated by superoxide dismutase (SOD) , catalase (CAT) and glutathione peroxidase (GPx) in the SM glands of SIBU treated rats. The analysis of thiobarbituric acid reactive substances (TBARs) will be used as a marker of lipid oxidative damages. The work was authorized by CEUA Local (FOA Protocol / UNESP n ° 00301-2016). Twenty-four Wistar rats (4 months / 350-450 g) will be divided into three groups and treated for 28 consecutive days by intragastric gavage with 6 and 10 mg / kg body weight of SIBU, SBU6 and SBU10, respectively, and the group Control (CON), which will only receive dimethylsulfoxide vehicle and saline solution during the same period. At the end of the treatment, the animals will be weighed and euthanized by exsanguination under general anesthesia. The SM glands will be removed and sequentially stored at -80øC until analysis. The normality and homoscedasticity of the data will be analyzed and they will be submitted to the most suitable parametric or non-parametric test. For all tests, the rejection level of the null hypothesis will be set at 5% (p <0.05).
News published in Agência FAPESP Newsletter about the scholarship: